Search results
Tematy dnia
23 paź 2024 · Merck’s KEYTRUDA® (pembrolizumab) Receives 30th Approval From European Commission With Two New Indications in Gynecologic Cancers. October 23, 2024. CDC’S ACIP Recommends Merck’s CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Pneumococcal Vaccination in Adults 50 Years of Age and Older. October 19, 2024.
- FDA Approves Merck’s WINREVAIR™ (sotatercept-csrk), a First-in-Class ...
WINREVAIR is the first FDA-approved activin signaling...
- FDA Approves Merck’s WINREVAIR™ (sotatercept-csrk), a First-in-Class ...
View Merck's news releases for up-to-date information about the company. You can filter the News section by business unit, type, year and month. Check out Merck's news release and keep up with our latest events and updates here!
2 dni temu · RAHWAY, N.J.-- (BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the third quarter of 2024. “Our third-quarter results were strong, as we continue to make progress heading into 2025 and beyond," said Robert M. Davis, chairman and chief executive officer, Merck.
26 mar 2024 · WINREVAIR is a first-in-class biologic that improves exercise capacity and functional class in adults with pulmonary arterial hypertension (PAH). The FDA approval is based on the Phase 3 STELLAR trial, which showed significant benefits of WINREVAIR on top of background therapy.
2 dni temu · RAHWAY, N.J., October 31, 2024--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the third quarter of 2024.
20 wrz 2023 · Merck, a leading science and technology company, today announced two new strategic drug discovery collaborations aimed at harnessing powerful artificial intelligence (AI)-driven design and discovery capabilities, further advancing the company’s research efforts.
2 dni temu · Oct 31 (Reuters) - Merck & Co , opens new tab posted higher-than-expected third-quarter earnings on Thursday on strong sales of its blockbuster cancer treatment Keytruda, but the U.S. drugmaker ...
